AC0078 – TRK Inhibitor

AC0078 is a novel small molecule inhibitor of tropomyosin receptor kinases (TRK). This family of signaling proteins is implicated in oncogenic rearrangements that result activated fusion kinases found in a many adult and pediatric cancers. AC0078 has shown potent and selective activity against wild-type and mutant TRKs in kinase enzyme and cell-based assays.

AC0078 is currently being studied in multiple disease models to establish its efficacy, pharmacokinetic and safety parameters ahead of anticipated clinical trials.